Effects of Nicorandil on Microvascular Dysfunction in Patients With STEMI Undergoing Primary PCI
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 170 participants.
Also called NCT06787430
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 170 participants
- Registry
-
NCT06787430
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT06787430. Randomized; triple masking; primary purpose treatment. Start 2026-03-01 (anticipated); primary completion 2026-12-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effects of Nicorandil on Microvascular Dysfunction in Patients With STEMI Undergoing Primary PCI
- Acronym
- NORMAL
- Condition
- STEMI - ST-segment Elevation Myocardial Infarction
- Intervention (Drug)
- nicorandil
- Intervention (Drug)
- Saline (NaCl 0,9 %) (placebo)
- Lead sponsor
- China National Center for Cardiovascular Diseases
Record details
- Record id
cardio:ct-nct06787430- Content hash
22d7cb66aa9c60b60e5f15797a6072dbe804255045bda6ebafe97e001af10edd